Open Access

Mosapride combined with probiotics on gastrointestinal function and growth in premature infants

  • Authors:
    • Ai‑Mei Zhang
    • Zhi‑Qun Sun
    • Li‑Ming Zhang
  • View Affiliations

  • Published online on: April 13, 2017     https://doi.org/10.3892/etm.2017.4340
  • Pages: 2675-2680
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to investigate the effects of mosapride combined with probiotics on gastrointestinal function and growth and development in premature infants. A total of 240 premature infants treated at Weifang People's Hospital between June 2012 and May 2015 who matched our criteria were randomly divided into three groups of 80 cases each. Group A received routine treatment, group B received routine treatment combined with live B. subtilis and E. faecium granules with multivitamins (Medilac‑Vita), and group C received routine treatment and Saccharomyces boulardii sachets (Bioflor). Mosapride was administered to patients in groups B and C to promote intestinal peristalsis. Gastrin and bilirubin levels, as well as jaundice fade time, were recorded. Growth and development condition (i.e., head circumference and weight), duration and incidence of feeding intolerance (FI), as well as other symptoms were also analyzed. By day 14, gastrin concentrations in groups B and C were significantly higher than those in group A (P<0.05). Serum bilirubin levels in groups B and C showed a progressive decline from day 7 to day 14, and jaundice duration in group A was significantly longer (P<0.05). Furthermore, at 2 weeks, the average weight growth rate and head circumference were significantly greater in groups B and C, weight loss recovery time was shorter, and EUGR incidence was lower (P<0.05). The incidence rate of gastric retention and FI were lower in groups B and C than group A (P<0.05), and neonatal hyperbilirubinemia, parenteral nutrition‑associated cholestasis, necrotizing enterocolitis, and neonatal sepsis incidence was significantly lower in groups B and C (P<0.05). Mosapride combined with probiotics can effectively reduce FI incidence in premature infants, shorten enteral feeding time, promote the absorption of required nutrients, and promote the development and recovery of early physiological weight loss in preterm infants.

Related Articles

Journal Cover

June-2017
Volume 13 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang AM, Sun ZQ and Zhang LM: Mosapride combined with probiotics on gastrointestinal function and growth in premature infants. Exp Ther Med 13: 2675-2680, 2017
APA
Zhang, A., Sun, Z., & Zhang, L. (2017). Mosapride combined with probiotics on gastrointestinal function and growth in premature infants. Experimental and Therapeutic Medicine, 13, 2675-2680. https://doi.org/10.3892/etm.2017.4340
MLA
Zhang, A., Sun, Z., Zhang, L."Mosapride combined with probiotics on gastrointestinal function and growth in premature infants". Experimental and Therapeutic Medicine 13.6 (2017): 2675-2680.
Chicago
Zhang, A., Sun, Z., Zhang, L."Mosapride combined with probiotics on gastrointestinal function and growth in premature infants". Experimental and Therapeutic Medicine 13, no. 6 (2017): 2675-2680. https://doi.org/10.3892/etm.2017.4340